Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

y's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird,

Director of Public Relations

PAREXEL International

Tel: +781-434-4409

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications

Tel : +617-779-1817

Email : rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 By now, if you ... not living on this planet. The awareness campaign has brought ... has helped to raise over $88.5 Million (and counting) for ... and some companies are starting to as well. ... Orlando, Florida , who actually works with ALS sufferers ...
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014  Hill-Rom Holdings, ... listen to a management presentation at the Morgan Stanley ... p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ... be available one hour after conclusion of the live ...
(Date:8/27/2014)... North American lighting leader OSRAM SYLVANIA ... the new OSRAM ITOS ® PHASER ® 3000, ... microscopy, endoscopy and surgical head lamps that delivers the same ... lamp life. "We,re honored to be recognized by ... new technologies of the past year," said Andreas Osten ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... in health care spending for commercially insured individuals is ... rather than increased use, according to a new study ... Policy & Clinical Practice, published in the August issue ... , There is increasing concern that consolidation in the ... by payers and, ultimately, consumers," said Carrie Colla, PhD, ...
(Date:8/27/2014)... 27, 2014 Scientists at The Scripps Research Institute ... signaling pathway can be associated with alcohol dependence. ... called neurofibromatosis type 1 (Nf1), which TSRI scientists found ... research shows Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter ... , "This novel and seminal study provides insights into ...
(Date:8/27/2014)... Dr. Winifred S. Hayes, President and CEO ... better health outcomes through the use of evidence, is ... to the executive team effective August 25, 2014. As ... responsible for providing innovation, leadership, and direction in the ... all markets. , “Maura is a highly respected ...
(Date:8/27/2014)... and dad, especially when your infant looks at you ... prattling, but by listening and responding, they let their ... forming complex sounds and using language more quickly. , ... of Iowa and Indiana University that found how parents ... way infants communicate and use vocalizations. , The findings ...
(Date:8/27/2014)... 2014 Will Holbrook, CP LP, has ... has over 15 years of experience in the prosthetics ... Georgia with a Bachelor of Science degree with a ... He received his graduate degree in prosthetics at Northwestern ... have Will join us at Fourroux,” says Keith Watson, ...
Breaking Medicine News(10 mins):Health News:Tracking spending among the commercially insured 2Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Maura Connor Joins Hayes, Inc. as Vice President, Digital Publishing, Editor-in-Chief 2Health News:Parents, listen next time your baby babbles 2Health News:Parents, listen next time your baby babbles 3
... inadequate resources provided by the government to help the ... of treatment has left many stroke victims invalid. According ... with timely treatment and quality care. ,The ... victims with immediate brain scans, appropriate medication to dissolve ...
... a grant of $6 million for the Florida State ... for dyslexia in children.// The schedule involves understanding, ... grant will fund the creation of a National Institutes ... The center, which will be one of only four ...
... breast cancer who have been receiving the 30-year-old tamoxifen ... with the drug, Arimidex// under a new European licence ... AstraZeneca has stated that Arimidex, an aromatase inhibitor, will ... a partial course of tamoxifen.The license for this switch ...
... pass a law that would protect HIV/AIDS patient's rights to ... right// for a woman with the right to seek an ... ,India is supposedly the country with the highest number of ... this bill is being proposed to control this problem at ...
... the leading developmental disability. Statistics show that about 1.5 million ... a 10-17% increase in the disease ratio every year//. ... symptoms known to everyone the cause of the disease still ... brain developed by Dr. Stephen Grossberg, professor and chairman of ...
... taking part in an initiative to gauge if any ... who have suffered a stroke recently//. The MíTICO study ... Ictus. ,The study included patients from different Autonomous ... three months previously. By means of periodical controls, a ...
Cached Medicine News:Health News:Research Fund for FSU to Eradicate Dyslexia 2Health News:New Law On HIV/AIDS To Be Implemented At The Monsoon Session Of Parliament 2Health News:iSTART Brain Model Reveals the possible Cause of Autism 2Health News:iSTART Brain Model Reveals the possible Cause of Autism 3
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Iso-Electric Determination Kit; contains 1 bottle of 40 nm Naked Gold Iso-Electric Determination Kit to optimize gold conjugation of antibodies...
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: